Page 3 - Bharat Biotech

Hundreds of millions of Covid vaccines in India to expire in September

Covaxin has a shelf life of 12 months, while Covishield, the vaccine that accounted for nearly 80% of India's vaccinations, has a shelf life of nine months

Paraguay cancels orders for one million doses of Covaxin, say sources

Media reports cite quality issues; sources say Bharat Biotech had stopped production and exports in April, any pending orders stand cancelled

Bharat Biotech's Covaxin phase-3 trial concluded successfully at AMU

The phase-3 trial for Covaxin was done in collaboration with the Indian Council of Medical Research (ICMR) and BBIL

Germany to recognize Bharat Biotech's COVAXIN for travel from June 1

WHO in November last year issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2

FDA lifts hold on clinical trials for phase 2,3 for Covaxin: Ocugem

"We're extremely pleased that we can proceed with our clinical trials for Covaxin our whole virus inactivated COVID-19 vaccine candidate," Dr Shankar Musunuri, CEO and Co-Founder, Ocugen Inc said

CEPI funds Bharat Biotech consortium project for variant-proof Covid-19 jab

CEPI has till date announced funding for nine such projects including the Bharat Biotech one

NTAGI meet this week to review vaccine data for 5-12 age group

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

Bharat Biotech must address vaccine issues raised by WHO, says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that Bharat Biotech addresses the issue immediately to avoid the cancellation

DCGI grants EUA to Corbevax for those aged 5-12, Covaxin for 6-12 age group

DCGI has granted emergency use authorisation for Biological E's Covid-19 vaccine Corbevax and Bharat Biotech's Covaxin

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years

Ocugen to commercialise Covaxin in Mexico, working on US market too

Covaxin has EUA in Mexico for use in adults; data submitted for EUA for children aged 2-18 years

Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold

WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP (good manufacturing practice) deficiencies in the Bharat Biotech's plants

SII to give free Covishield vials to pvt vaccination centres: Here's why

Vaccine majors SII and Bharat Biotech said they have decided to cut prices of precaution dose of their respective Covid-19 vaccines to Rs 225 per shot for private hospitals after discussion with govt

SII, Bharat Biotech cut Covid vaccine prices for pvt hospitals to Rs 225

SII and Bharat Biotech have been major suppliers of Covid-19 vaccines to the government so far

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech

Various countries including Australia, have recognised Covaxin for facilitating travel

2 Covaxin shots provide high immunity in breakthrough cases: ICMR

A recent ICMR study has shown that breakthrough cases after full vaccination with Covaxin have shown a significant increase in the immune response against coronavirus' variants of concern

Don't slack off

Vaccination programme cannot lose govt attention

'No impact of WHO action on Covaxin, not supplied to any UN agency'

Bharat Biotech also said the WHO announcement will not impact the Ocugen trials

No issue with Covaxin certificate: Bharat Biotech on WHO suspending vaccine

Bharat biotech says there are no issues with Covaxin or its certification, further we will focus on pending facility maintenance, has no supply commitments pending for UN agency.

No impact on efficacy, safety of Covaxin: Bharat Biotech on WHO suspension

The vaccine manufacturer has said that the company is slowing down the production of Covaxin for facility optimization.